Program
anagliptin
Also written as “Anagliptin” and “SK-0403”.
Its studies are mostly in Diabetes Mellitus, Type 2, led by 3 companies.
Drug pageAnagliptin: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| JW Pharmaceuticalits history only | 31 open or running | phase 4since Jan 21, 2026 | Feb 6, 2012 | Mar 31, 2027phase 4 · NCT07442006 |
| Kowa | 20 open or running | phase 2since Jul 22, 2010 | May 25, 2010 | none ahead |
| Sanwa Kagaku Kenkyushoits history only | 10 open or running | phase 2since Sep 19, 2007 | Sep 19, 2007 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Kowa only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 25, 2010First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT01131091 · 30 enrolled · United States
- Jul 22, 2010Phase 2 study in Diabetes Mellitus, Type 2NCT01169090 · 620 enrolled · United States
TargetBeta
“An orally available, potent, selective inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule
Other programs on DPP4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sitagliptinrule | Merck | phase 4 | 123 |
| Linagliptinrule | Boehringer Ingelheim | phase 4 | 96 |
| gemigliptinrule | LG Chem | phase 4 | 30 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
| cofrogliptinrule | Haisco Pharmaceutical Group | no phase | 1 |
Studies
All 2 Kowa leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01169090Diabetes Mellitus, Type 2 · United States | 2 | Completed | Jul 2011 | 620 |
| NCT01131091Diabetes Mellitus, Type 2 · United States | 1 | Completed | Nov 2010 | 30 |
How it is read
Names in the registry
- “Anagliptin”, 4 entries
- “SK-0403”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.